The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
EBITDA before special items decreases to €4.08 billion (7.4%)
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
Subscribe To Our Newsletter & Stay Updated
